Oxford BioMedica PLC (OXBDF)

[marcusl2]

Great news if we keep on getting this work from Novartis!

CLL is one of the most common types of adult leukemia

Novartis next generation CAR-T cell therapy CTL119 combined with ibrutinib shows high rate of responses in CLL patients
MAY 31, 2017
Eight of nine evaluable patients tested had no signs of CLL in their bone marrow at three months.
CTL119 is a humanized CD19-directed CAR-T cell therapy being developed in collaboration with the University of Pennsylvania
Novartis is committed to advancing a portfolio of next-generation CAR-T cell therapies

HTTPS://www.novartis.com/news/media-releases/novartis-next-generation-car-t-cell-therapy-ctl119-combined-ibrutinib-shows-high

In addition our CAR-T cell program continues to advance in a range of hematological and solid tumors including emerging programs in Chronic Lymphocytic Leukemia (CLL) and Follicular Lymphoma (FL).

The Innovative Medicines Oncology business unit is advancing the Novartis Immuno-oncology (IO) strategy to win with CAR-T and accelerating development of second generation combinations with PD-1.

HTTPS://www.sandoz.com/news/media-releases/meet-novartis-management-investor-event-novartis-highlights-focus-innovation-and